Opinion Paper

The snapshot of metabolic health in evaluating micronutrient status, the risk of infection and clinical outcome of COVID-19

Dimitris Tsoukalas a, b, *, 1, Evangelia Sarandi b, c, **, 1, Spyridoula Georgaki b, 1

* European Institute of Nutritional Medicine, 00198 Rome, Italy
** Metabolomic Medicine, Health Clinic for Autoimmune and Chronic Diseases, 10674 Athens, Greece
1 Laboratory of Toxicology and Forensic Sciences, Medical School, University of Crete, 71003 Heraklion, Greece

1. Introduction

In March 2020, the World Health Organization declared the outbreak of acute respiratory syndrome coronavirus 2 (SARS-COV-2/COVID-19) a global pandemic. At the time of writing, the viral infection accounts for 2.8 million deaths and 132 million infected cases [1]. Although the underlying disease mechanisms have not yet fully unraveled, it seems that common inflammatory cascades, also known as ‘cytokine storm,’ are responsible for the spectrum of clinical manifestations; from asymptomatic cases, loss of smell or/and taste senses, to mild upper respiratory tract infections and acute respiratory distress syndrome (ARDS), characterized by severe organ failure and eventually, death [2,3]. Among the most prominent recruited molecules, IL-1, IL-6, tumor necrosis factor (TNF-α), and interferon (IFN) levels rise abruptly, leading to uncontrolled inflammatory responses and, eventually, tissue damage due to aberrant cellular interactions [4]. Several factors have been acknowledged to affect whether patients will develop severe COVID-19 phenotype, which, as defined by the Centers for Disease Control and Prevention (CDC), includes hospitalization, admission to the intensive care unit, intubation or mechanical ventilation, or death [5].

Clinical data on COVID-19 have demonstrated that individuals of older age (over 65), immunocompromised, presenting with comorbidities, including cancer, lung and heart disease, as well as patients with metabolic complications, such as type 2 diabetes...

https://doi.org/10.1016/j.clnesp.2021.06.011
2405-4577/© 2021 The Authors. Published by Elsevier Ltd on behalf of European Society for Clinical Nutrition and Metabolism. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
T2D), obesity, metabolic syndrome, share major risks in exhibiting a more severe disease course [6,7]. The role of metabolism emerges as pivotal in disease susceptibility and recovery, seeing that, during infections (COVID-19 included), metabolic perturbations influence the effectiveness of immune responses [8–10].

The role of metabolism in COVID-19 can be summarized as:

a. Individuals with poor metabolic health and/or micronutrient deficiencies share a high risk for infections
b. Altered metabolism is a risk factor for the progression to severe disease
c. Metabolic health and/or micronutrient deficiencies define the time of recovery and post-COVID complications

The aim of the present article is to discuss current advances in the assessment of metabolic health and micronutrient status and their challenges. Here, we present metabolomics as a sensitive, non-invasive and scalable tool to early diagnose unfavorable metabolic conditions that put individuals at risk of infections and severe infection complications, and to monitor the effect and efficacy of interventions.

2. Metabolic health and micronutrient status as a risk factor for COVID-19

Metabolic health has gained increasing attention recently due to its central role in COVID-19 associated mortality. Assessment of the risk factors for hospitalization among 900,000 patients in the U.S. revealed that 63.5% of them were attributed to cardiometabolic factors (diabetes mellitus, obesity, hypertension, and heart failure), thus could have been prevented [11]. Even though metabolic disease, such as T2D, was once thought to be a characteristic of obese metabolic disease pathogenesis [13]. Insulin resistance has been compared to healthy, stressing the need to look at the early stage of unfavorably unhealthy, lean individuals were characterized by a more metabolic overload and, together with the over activation of anti-microbial proteins and the management of immune cells’ growth and response are inclusive responsibilities of certain micronutrients [19].

Thus, maintaining micronutrient adequacies is crucial for reducing the risk of infection and disease progression, either through their roles in the normal function of the immune system or through the promotion of metabolic health. The origin of micronutrient deficiencies may be poor, low-nutrient dietary choices, which in turn alter the microbiota equilibrium, disturbing their production of vitamins and molecules, and promoting gut permeability, further aggravating loss of micronutrients obtained from food [21]. It has been suggested that the immunological responsiveness diminishes from a shift in the food systems, from a nutrient-rich and healthy diet to a high calorie one lacking a range of nutrients, to cover modern lifestyle requirements [22,23]. Collectively, daily exposure to unsustainable diets promotes a metabolic overload and, together with the over activation of nutrient-specific signals, impairs the immune function [23].

The following paragraphs present a summary of specific immune cell activities that are influenced by the presence of nutrients, recent evidence on associations between micronutrient deficiencies and infections, as well as the outcomes from nutrients replenishment and disease course.

3. Micronutrients: the master regulators of the immune system

Among the significant immunity-supporting nutrients are the vitamins A, C, D and E, zinc, magnesium, omega-3 Polyunsaturated Fatty Acids (PUFA’s) and probiotics. Importantly, the levels of several of these nutrients are insufficient in cases of respiratory tract infections, including COVID-19 [24]. The exact role of these nutrients has been discussed extensively elsewhere, and here we provide a brief description [20,25–27]. Vitamin A promotes the epithelial barrier function and phagocytic capacity, with lower levels being associated with increased vulnerability to pathogens and reduced responses from dendritic cells (DCs) and macrophages. It also favors adaptive immunity with antibody production and enhances cytotoxic activity [28–30]. Like vitamin A, vitamin C improves cytotoxic T lymphocytes activity and antibody production and is also involved in the epithelial cohesion process. Moreover, it offers antioxidant protection, which has been strongly associated with COVID-19 pathogenesis [31–33]. As demonstrated elsewhere, the immunological memory is hindered in humans deficient in vitamin C, and the incidence of severe respiratory infections increases [34,35]. Due to the therapeutic benefits of vitamin C against respiratory diseases [36,37], it serves as a key interventional mechanism in COVID-19 management [38,39].

Innate immunity is also stimulated by vitamin D levels, which improve resistance to infectious agents by upregulating the
production of anti-microbial peptides. The most important immunological benefit of vitamin D, which is generally inhibitory for adaptive immunity, is the monitoring of DCs activity, vital for antigen-presenting signals and acquiring of immunological tolerance. Vitamin D deficiency has been inversely associated with the incidence of respiratory illness in another cohort [41]. In COVID-19 cases, vitamin D administration may alleviate cytokine storm cascades [42] and provide protection from the pro-inflammatory ACE2-mediated pathway as a negative regulator of the angiotensin-II response [43]. An ongoing clinical trial on the use of vitamin D and other nutraceutical compounds at the Queen Mary University of London aspires to elucidate their clinical significance against COVID-19 (NCT04330599). As for vitamin E, it facilitates the communication between DCs and T helper cells [44] and acts as a pro-oxidant scavenger [45]. Vitamin E supplementation has been associated with a reduced risk of infections in the elderly, as well as with lower rates of hospital admissions for tobacco smokers who develop pneumonia [46,47].

Adequate zinc levels help to sustain sufficient populations of B and T precursor cells in the bone marrow and thymus, as well as to preserve the machinery of innate immunity, such as natural killer cells (NKs) and macrophages [48]. Importantly, concerning COVID-19, zinc has been used to interfere with viral RNAs and to prevent their replication [49]. This implies that zinc levels are associated with enhanced host responses against viral infections. Of note, zinc replenishment reversed NKs activity in patients with sickle cell anemia and improved T cell numbers in the elderly [50,51]. Recent literature on respiratory tract infections shows that zinc supplementation correlates with lower mortality rates and lower incidence in adults and children [52,53].

Magnesium is one of the most significant life-sustaining compounds, mainly required as a cofactor for the optimal function of numerous enzymes, for genomic integrity regulation, as well as for the regulation of secondary messaging and ion channels [54]. Deficiencies have been inherently associated with impaired immune responses, increasing the levels of pro-inflammatory molecules, such as TNF-α and depleting the anti-inflammatory cytokines [55]. Conversely, magnesium replenishment seems to also regulate the hemostasis cascade and tissue factor expression by decreasing NF-κB activation [56]. Recent literature demonstrates that adequacies in intracellular magnesium help to mediate NKs and CD8+ cytotoxic T lymphocytes activities [56]. Together, insufficient levels of magnesium promote cytokine storm mechanisms and increase the risk of intravascular thrombosis. Of note, the enzymes that promote vitamin D catabolism require magnesium as a cofactor [57]. Thus, maintaining optimal levels of magnesium indirectly affects the above-mentioned monitoring of immune responses, coordinated by vitamin D. Data on a COVID-19 observational study have demonstrated the beneficial effect of magnesium, vitamin D and B12 supplementation in lung function deterioration and ICU admission [58].

The immunomodulatory effects of omega-3 PUFAs have been extensively investigated in the area of inflammatory diseases, as they are negative regulators of pro-inflammatory compounds production, namely eicosanoids, cytokines and adhesion molecules [26]. Regarding COVID-19 data, in a recent pilot study of 100 patients, a tendency of reduced mortality risk was correlated with the levels of Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) acids, although more studies are warranted to support the positive effects of omega-3 PUFAs supplementation [59]. Another prophylactic aspect of omega-3 PUFAs concerns the production of their anti-inflammatory metabolites, resolvins and protectins. The therapeutic potential of these compounds has been presented in several cases of infections, and especially in RNA viruses [60,61].

Probiotics are colonies of bacteria and yeasts, localized in various sites across the body (skin, oral mucosa, lung, gastrointestinal tract and other anatomical regions). During infections, the reported fluctuations in their relevant concentrations propose another feature of immune response modulation [62–64]. The gastrointestinal tract supports the largest amount of microbiota, which comes with increased variability among individuals. Nutrition, obesity, as well as disease contribute to the alteration of gut microflora composition. In fact, patients with chronic diseases and metabolic syndrome present with dysbiosis, which means imbalances in the relevant concentrations of the beneficial microflora [65,66]. It has also been postulated that COVID-19 may interfere with the host’s microbiome whereas, lung microflora composition regulates immune defenses to viral insults [67,68]. The therapeutic properties of probiotics administration have been demonstrated in the alleviation of ventilator-associated pneumonia, which can be translated in similar cases of pneumonia during COVID-19, adjunctive to the preventive measures [69].

Recently, data evaluating the impact of certain micronutrient replenishment on COVID-19 onset demonstrated that probiotics, omega-3 PUFAs, multivitamins and vitamin D supplementation provided the female population with significantly lower risks of infection [70]. However, despite these promising outcomes, longitudinal interventional clinical trials assessing the effect of multiple micronutrients with an efficient toolset is of the essence, taking into consideration that micronutrients act in synergy to fulfill their biological functions and self-reported data account for subjective contributions in the studies [71]. Overall, even though there is sufficient knowledge on the critical roles of micronutrient status and metabolic health on infectious diseases, targeting the metabolism of the host seems attractive, yet we lack a unified tool for their assessment.

4. Metabolomics: the lens to view metabolic health and disease

Critical illnesses and infectious disease pandemics, like COVID-19, need to include assessment tools of metabolic health and nutritional status of individuals as a first-line strategy, but also after hospitalization. Metabolomics, an emerging domain in omics, offers the ability to dissect the circulating metabolites of cells, tissues and organs (metabolic profiling) in various biofluids (blood, urine, saliva) [72]. Nutritional deficiencies and metabolism are inherently linked, as metabolic reactions require the presence of cofactors and coenzymes, in order to proceed. Coenzymes are organic molecules that bind to the active site of the enzyme and enhance the binding of the reaction substrate, such as vitamins and amino acids. On the other hand, cofactors may be molecules of organic or inorganic origin, such as metal ions (Mg2+, Zn2+, Fe2+) [36] (Fig. 1).

According to Human Metabolome Database (HMDB), there are already 114,304 metabolite entries, including 8,196 human endogenous metabolites [73]. With the advent of bioinformatics and spectrometric methodologies for metabolomics analysis, it is plausible to extract data on key metabolic processes, such as glycolysis and gluconeogenesis, fatty acid oxidation, oxidative stress, mitochondria function, as well as the metabolism of protein and carbohydrates, neurotransmitters and gut microbiota [72]. The afore-mentioned pathways are affected by nutritional delivery, metabolic perturbations, dysbiosis, disease and environmental pressure. Metabolomics has been applied in several clinical aspects for over three decades exceeding 19,000 published articles in humans. From disease prediction to pharmacometabolomics, metabolites can either predict the onset of a disease years before symptoms appear or reveal the most effective pharmacological...
drug, coupled with nutritional support against an acute or chronic disease [74]. This technology is not new, considering that biochemical analyses for disease risk assessment in cardiovascular complications and diabetes paradigms utilize the information derived from specific metabolites, such as cholesterol and glucose [75,76]. In addition, inborn errors of metabolism have been diagnosed for decades through the quantification of metabolites [77]. Metabolomics comes to broaden our perspectives on health and disease dynamics by extracting informative biomarkers to illustrate the individual’s metabolic health and reveal unnoticed micronutrient deficiencies.

### 4.1. Metabolomics for micronutrient deficiencies detection

Malnutrition comprises one of the main reasons for ICU admission in cases of acute diseases, serving as a biomarker of disease progress and severity [78]. In addition, respiratory tract infections have been linked to key nutrient deficiencies, as well as an improved disease course upon nutrient replenishment [19,20]. Collectively, the cytokine storm-induced ARDS indicates the similarities in pathogenesis that might be managed through nutritional restoration. For this reason, concerted efforts for the establishment of efficient nutrition support protocols in hospitalized patients have been made, as effective therapeutic ailments targeting disease causalities have not yet been discovered or validated [79,80].

The presence of micronutrient deficiencies comprises a hallmark of metabolic disruption and disease [21]. Patients experience no symptoms until the severe deterioration of tissues or organs. Notably, recent literature describes that more than 20% of global mortality is attributed to poor nutritional habits, with chronic health complications, like cardiovascular disease, cancer and diabetes ranking as the leading causes of death [81]. The diagnosis of micronutrient inadequacies is challenging, regarding the sensitivity of the biomarkers, the optimal levels of nutrient intake and the special populations being at risk. The paradigm of B12 deficiency assessment with the help of metabolomics represents an approach to overcome these barriers.

#### 4.2. The paradigm of B12 deficiency diagnosis

The adequate intake for vitamin B12 (also called cobalamin), relies solely on diet resources, as it cannot be synthesized by the human genome. The main causes of B12 inadequacy are suboptimal dietary intake and malabsorption. In order to be processed, vitamin B12 is transported into the cells via protein transporters, namely haptocorrin (HC), intrinsic factor (IF) and transcobalamin (TC). The functional role of B12 is the promotion of adenosylcobalamin and methylcobalamin-dependent enzymes for the production of succinyl-CoA from methylmalonyl-CoA and of methionine from homocysteine, respectively. The first reaction results in the replenishment of the Tricarboxylic acid cycle (TCA cycle), and as for the second, it yields to the production of tetrahydrofolate, which is a folic acid derivative vital for nucleic acid biosynthesis [82].

Metabolomics might be useful in the diagnosis of B12 deficiency, independently of the origin of the inadequacy, as suboptimal levels of B12 lead to the accumulation of methylmalonic acid and homocysteine in the blood, which can both be captured with sensitivity [83,84], before resulting to methylmalonic acidemia and hyperhomocystinemia [85]. Methylmalonic acidemia has been correlated with cognitive impairments, kidney disease, and pancreatic inflammation, whereas hyperhomocystinemia associates with elevated risk for developing acute coronary syndromes, peripheral vascular disease, myocardial infarction and stroke [86,87]. Although conventional B12 deficiency is assessed via total serum levels, this method evades capturing the bioavailability of B12, as a large amount of B12 (~80%) is bound to HC [88], thus decreasing the diagnostic reliability. The assessment of methylmalonic acid levels in human biofluids with metabolomic-based platforms captures B12 deficiency more efficiently, as the reaction catalyzed by the responsible enzyme (methylmalonyl-CoA synthase) and promoted by B12 does not require the presence of other vitamins [89,90]. Increased methylmalonic acid may also be present in cases of renal dysfunction, requiring careful evaluation and discrimination of distinctive B12 deficiency [90]. The diagnostic value of B12 deficiency increases with the assessment of Holo-TC.
which is the bioactive form of B12 that, bound to TC, is furthermore dispensed to systemic circulation for processing. The accuracy increases when employing holo-TC analysis, owing to the ability to capture B12 insufficiencies in special populations [91]. Therefore, combining the conceptions of metabolomics, paired with informatic diagnostic algorithms, is of the essence in order to apply accurate, specific and sensitive diagnostics in the field of nutritional insufficiencies.

4.3. Metabolomics to assess metabolic health

A large number of metabolomic studies on T2D and metabolic syndrome patients have identified critical pathways that are implicated in the development of metabolic disease. Specifically, the metabolism of BCAAs, lipids, acylcarnitines and carbohydrates, as well as the metabolites involved in the energy production pathways (TCA cycle) and the microbiome, comprise the most important affected pathways [92]. Of note, some of these pathways have been directly related to insulin resistance and, therefore, may serve as predictive biomarkers of metabolic disease progression. Amino acid metabolism has long been related to insulin function, and several metabolomic studies have concluded that BCAAs, including valine, leucine, isoleucine and their downstream metabolites would be useful predictive biomarkers. It has been shown that BCAAs levels are useful to distinguish insulin-resistant from insulin-sensitive individuals, that their levels are related to disease progression from pre-diabetes to diabetes, and they are accurate predictors of therapeutic interventions [15]. The proposed molecular mechanism by which BCAAs levels may reflect insulin resistance involves several aspects (Fig. 1): A. Insulin is a negative regulator of the enzymes that produce a-ketoacids or 2-ketoacids (2-ketociscaproate, 2-ketoisovalerate, 2-keto-3-methyl valerate), namely BCAA aminotransferase (BCAT) and branched-chain ketoacid dehydrogenase (BCKD) complex. Thus disrupted levels of BCAAs in relation to their downstream metabolites might indicate insulin signaling disruption [93,94]. Of note, these 2-ketoacids are also markers of insufficiency for vitamins B1, B3, B5, which act as coenzymes for BCKD complex. B. BCAAs have been shown to activate the mammalian target of rapamycin 1 (mTORC1), a known mechanism for insulin sensitivity regulation. Thus, increased levels of BCAAs may trigger insulin resistance [95]. C. BCAAs levels have been shown to be affected in hyperlipidemic state, playing a key role in the development of insulin resistance. A proposed mechanism includes that, in overnutrition and obese state, glucose and lipids catabolism are promoted, with concurrent suppression of the metabolism of BCAAs in the liver and adipose tissue, but not in the skeletal muscle. BCAAs accumulation in the skeletal muscle leads to increased generation of propionyl-CoA and succinyl-CoA, which supply the TCA cycle continuously, leading to a mitochondrial overload and defective fatty acid oxidation [96]. The accumulation of incomplete oxidized products, mitochondrial overload, cause mitochondrial stress, reduced insulin sensitivity and circulating glucose levels imbalances. D. Besides diet, BCAAs can be endogenously synthesized by gut bacteria, suggesting that gut dysbiosis may contribute to the accumulation of BCAAs and insulin resistance. Taken together, BCAAs have been associated with insulin resistance via multiple pathways, and even though the exact etiological mechanism remains to be elucidated, their predictive value holds promise for clinical application.

Lipidomic patterns have long been associated with metabolic diseases, and the measurement of certain lipids such as cholesterol, triglycerides and total fatty acids are used for the estimation of cardiometabolic risk. Advancements in metabolomics technologies have facilitated the in-depth analysis of fatty acids either free or as part of phospholipids, cholesterol esters and triglycerides, providing a quantitative and qualitative estimation of fatty acids composition. Several fatty acids have been linked to insulin resistance, namely stearic acid, palmitic acid and their monounsaturated derivatives oleic acid and palmitoleic acid and the omega-6 PUFAs, linoleic acid, and dihomo-gamma-linoleic acid (DGLA) [97–99]. However, due to the complex mechanism of lipid metabolism, there are several challenges to understand whether free fatty acids changes occur due to specific dietary foods containing these fatty acids or due to increased intake of carbohydrates, that result in de novo lipogenesis. Additional metabolites, such as 3-hydroxybutyric acid and acetocetate, which are ketone bodies produced through the oxidation of fatty acids in cases of insufficient glucose uptake, might be able to validate insulin resistance. In addition, some reported that the enzymes metabolizing linoleic acid and DGLA, namely delta-6 and delta-5 desaturase, respectively, are regulated by insulin [100,101]. DGLA is the precursor of the pro-inflammatory eicosanoids’ mediator, arachidonic acid. Thus, high enzymatic activity, mediated by insulin signaling dysfunction, might cause excessive production of eicosanoids. Similarly, the enzyme converting myristic, palmitic and stearic to myristoleic, palmitoleic and oleic, respectively, is delta-9 desaturase, and its activity has been shown to be affected upon insulin resistance, a state reflected by the mediated metabolites [102]. Thus, the evaluation of metabolite ratios with a dietary questionnaire might provide valuable insight on the hyperinsulinemia and/or insulin resistance state and as sensitive clinical diagnostic markers of insulin resistance, but also for monitoring the efficacy of applied interventions.

5. Metabolomic-based biomarkers for immune function assessment

The afore-mentioned nutrient deficits, acting on the immune system’s performance, require early identification by sensitive and reliable tools. Metabolomics focuses on the accumulation of specific metabolic intermediates, such as methylmalonic acid in the B12 paradigm, to assess the status of vital nutrients.

As described above, methylmalonate is a derivative of the metabolism of the BCAA valine and accumulates in the periphery upon vitamin B12 deficiency. Similarly, 2-ketoisovaleric acid, 2-ketociscaproic acid and 2-keto 3-methyl valerate are downstream products of valine, leucine and isoleucine catabolism, respectively, exhibiting elevations in the periphery in response to B complex vitamins inadequacies. The extraction of these metabolomic-based biomarkers provides a functional readout of a host’s immunometabolism, as different B vitamins coordinate different immune responses. Specifically, adequate energy production for immune cell activities, gut microbiota composition, fatty acid oxidation, reactive oxygen species (ROS) generation, T cell differentiation and regulation of inflammatory signaling, all comprise key components of B-vitamin mediated monitoring [103]. The sufficiency of beneficial gut microflora can be indirectly evaluated through the levels of vitamin B7 (biotin). This vitamin is endogenously produced by probiotic gastrointestinal bacteria and is required as a coenzyme to promote fatty acid biosynthesis, gluconeogenesis and amino acid metabolism. Biotin-dependent 3-methylcrotonyl-CoA carboxylase promotes leucine catabolism, and decreased enzymatic capacity is associated with the accumulation of 3-methyl crotonic acid and 3-hydroxyisovaleric acid in the biological fluids [104,105].

Apart from the anti-inflammatory properties of vitamin A, it also provides the cells with antioxidant protection. Lipid peroxidation is a sign of cell damage due to oxidative stress and leads to 8-oxo-2’-deoxyguanosine (8-oxo-dG) formation [106]. Vitamin A insufficiencies cannot compensate for the toxic load of ROS, leading to
increments in 8-oxo-dG levels. Maintaining redox balance to fight infections is in line with recent data, highlighting that mitochondria dysfunction is correlated with impaired immune responses [107]. Vitamin C acts as a reducing agent, therefore, restoring cellular antioxidant capacity. Together with 8-oxo-dG analysis, vitamin C deficiency is defined by the presence of 4-hydroxyphenylpyruvic and p-hydroxyphenyllactate, which are intermediates of tyrosine metabolism and require ascorbic acid as a cofactor [108]. The measurement of intermediate metabolites in the blood is a more accurate diagnostic approach, as circulating vitamin C is highly degradable [109]. Another biomarker of vitamin C adequacy is adipic acid, a marker of carnitine biosynthesis. Vitamin C is a vital compound of the enzymatic reactions involved in carnitine biosynthesis for successful lipid oxidation in mitochondria [110]. Thus, the presence of adipic acid in the biofluids indicates that fatty acid oxidation is interrupted due to carnitine insufficiency, and omega oxidation occurs in the peroxisomes, leading to elevations of the compound in the periphery [111]. In this context, indirect metabolic biomarkers associated with increased oxidative stress are also employed to assess vitamin E levels, which is a natural antioxidant in the membranes of all cells. The information acquired from the presence of 8-oxo-dG, p-hydroxyphenyllactate and quinolinic acid is translated to increased demands of pro-oxidant scavengers, such as vitamin E [112,113].

Vitamin D is distributed to the tissues and organs after being synthesized in the skin upon UV exposure, in the form of cholecalciferol or in the form of ergocalciferol, of dietary intake. At these stages, vitamin D is biologically inactive and requires two sequential hydroxylations: one in the liver, leading to the formation of 25-hydroxy-vitamin D and one taking place in the kidneys as well as in other cells such as T lymphocytes, to produce 1,25-dihydroxy vitamin D [114]. To exert its immunomodulatory effects, 1,25-dihydroxy vitamin D binds to DNA receptors to initiate protein synthesis [115]. Thus, 25-hydroxy-vitamin D measurement is the most accurate method to test vitamin D supplies in the body [116].

Zinc is involved as a cofactor in several biochemical reactions, enhancing the catalytic activity of enzymes and other proteins [117]. Apart from its role in antioxidant prophylaxis, it restores the metabolic imbalances of the TCA, thus promoting the normal function of mitochondria and oxidative phosphorylation, carbohydrate metabolism as well as fatty acids metabolism [118]. Intermediates of the TCA cycle, such as citrate, pyruvate or succinate, as well as a-linolenic acid of the omega-3 PUFAs catabolism, serve as sensitive indicators of zinc deficiency. Energy production in the form of ATP requires the presence of magnesium in order to be bioavailable, meaning that TCA intermediates including citrate, aconitate and succinate may serve as valuable compounds for the assessment of magnesium deficiency.

Metabolomic-based platforms can directly identify, among others, the omega-3 PUFAs, namely EPA and DHA, the above-mentioned monounsaturated and omega-6 PUFAs, correlated with insulin resistance (stearic acid, palmitic acid, oleic acid, palmitoleic acid, linoleic acid and DGLA), thus providing an overview of an individual’s pro-inflammatory and anti-inflammatory eicosanoids. Imbalances in the omega-6 to omega-3 ratios, owing to poor dietary choices, enzymatic dysfunction or malabsorption, result in elevated omega-6 fatty acids that are indicative of a pro-inflammatory state [119].

We conducted a search of the recent PubMed published literature (April 2021) for the topics “metabolomics” and “COVID-19”, which returned 130 results. After narrowing down the search for human studies, the results were 75. The aim was to collect all the research articles on metabolomics-based COVID-19 diagnostic biomarkers, resulting in 26 original article studies summarized in Table 1. Briefly, the main body of the studied populations consisted of molecularly tested positive COVID-19 patients compared to healthy individuals. The most recent candidate biomarkers participated in central metabolic pathways, including the metabolism of TCA, lipids and BCAAs. Interestingly, the presence of the afore-mentioned metabolites both as COVID-19 risk biomarkers and as putative insulin resistance biomarkers indicates the emergence of a pattern between metabolic health regulation and susceptibility to the infection. However, to what extent the impaired metabolic health aggravates the onset of infection or attenuates the immune responses leading to long-term health complications even after recovery, remain to be elucidated.

6. Metabolomics in post-COVID syndrome

COVID-19 has been associated with impairments in diverse organ functions, namely lung, cardiovascular, hepatic, neurological and cognitive [146,147]. The major immune responses, inclusive of COVID-19 infection that have been considerably described, are the host’s systemic inflammation and the induction of a pro-thrombotic state. Autoimmune complications have also been reported to occur upon the COVID-19 rehabilitation process [148]. The resilience of health issues in the convalescent COVID-19 patients raises the issue of the COVID-19 infection against the induction of chronic health conditions. The example of metabolomics may be useful in the early identification of high-risk populations.

Autoimmunity and viral epidemics interconnection, as well as the causal role of infections in autoimmunity presentation, have been extensively studied in cases of Kawasaki disease [149], Guillain-Barre syndrome [150], type 1 diabetes [151], systemic lupus erythematosus [152], multiple sclerosis [153], autoimmune hemolytic anemia [154] and rheumatoid arthritis development [155]. Nowadays, COVID-19 recuperating patients have already been associated with the aforementioned autoimmune conditions [150,156-159], as well as with the presence of anti-phospholipid antibodies, which increase the risk of thrombosis [160].

The marked depletion in the populations of innate and adaptive immune cells emerges as a key regulator of the immunosuppression and subsequent cell redistribution that promotes loss of cell tolerance and autoimmunity. Specifically, the levels of eosinophils and NKs have been reported to decrease in cases of COVID-19 infection, leading to a compromised IFN-mediated response, and defective defenses against the viral invasion [161-163]. In the same context, CD4+ regulatory and CD8+ effector T and B cells have exhibited reductions in the periphery of acute COVID-19 cases [163]. Additionally, the experimental removal of lymphoid organs in animal models resulted in the infiltration of various tissues with T cells, induction of inflammation and the development of auto-antibodies. It has been postulated that, in order to fill the gap of peripheral immune cell scarcities, the organism seems to be transitioning to an anti-self-renewal state, implicating immune cell lineages that progressively lose their tolerance [164].

The hyperactivation of the cytokine cascade (cytokine storm), the viral breach in the lymphoid organs and the expression of spike protein’s ligand, ACE2, by the lymphocytes comprise a suggested biological explanation towards the presence of lymphopenia [165]. Although the role of metabolism has been relatively unvisited in the subject, severe metabolic imbalances, such as metabolic acidosis, have been directly linked to COVID-19 clinical manifestations [166,167]. It has been demonstrated that elevations in serum lactic acid levels compromise T cell metabolism and function, leading to T cell reduction [168]. Taking into consideration that hyperlactatemia is a biomarker of hypoxia [169], monitoring the levels of this particular metabolite might not only serve as a risk assessment strategy but also as a tool to minimize the potentials of autoimmunity appearance.
Table 1
Summary of the latest clinical studies in metabolomics for the extraction of COVID-19 diagnostic biomarkers.

<table>
<thead>
<tr>
<th>Author(s), Year</th>
<th>Population Group allocation</th>
<th>Specimen</th>
<th>Method</th>
<th>Metabolic profile in CP</th>
<th>Pathways</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shen et al. (2020)</td>
<td>N = 102 53 H, 49 CP</td>
<td>serum</td>
<td>Targeted, UPLC-MS/MS</td>
<td>Low sphingolipids, glycerophospholipids, glutamate, arginine, N-(1-arginino)-succinate, citrulline, ornithine, glutamine, 2-oxoglutarate, N-acetyl-L-glutamate, urea, fumarate</td>
<td>Lipid metabolism, arginine metabolism</td>
<td>Severe cases can be classified using a machine learning method based on the proteomic and metabolomic profiling.</td>
</tr>
<tr>
<td>Thomas et al. (2020)</td>
<td>N = 49 16 H, 33 CP</td>
<td>serum</td>
<td>Untargeted, Targeted UHPLC-MS</td>
<td>Low tryptophan, serotonin, indolepyruvate, gluconeogenic amino acids (alanine, serine, glycine, glutamine, histidine), sulfur amino acids (cysteine, taurine), acylcarnitines</td>
<td>Tryptophan metabolism, glycolysis, pentose phosphate metabolism, fatty acid metabolism</td>
<td>The obtained serum metabolome reflects IL-6 function, providing promising therapeutic targets.</td>
</tr>
<tr>
<td>Song et al. (2020)</td>
<td>N = 76 26 H, 50 CP</td>
<td>plasma</td>
<td>Untargeted, Targeted UPLC-MS/MS</td>
<td>Low tryptophan, glutamine, histidine, isoleucine, apolipoprotein A1 and A2 in HDL, cholesterol in HDL, High kynurenic acid, a-1-acid glycoprotein, glutamic acid, aspartic acid, glucose, taurine, cystathionine, phenylalanine, triglycerides in HDL, LDL and VLDL, cholesterol in VLDL, phospholipids, apolipoprotein A1 and B in VLDL and IDL,</td>
<td>Lipid metabolism, β-oxidation, TCA cycle, amino acid metabolism</td>
<td>Exosomes might be associated with COVID-19 pathogenesis.</td>
</tr>
<tr>
<td>Klimhofer et al. (2020)</td>
<td>N = 42 25 H, 19 CP</td>
<td>plasma</td>
<td>Untargeted NMR, LCMS</td>
<td>Low tryptophan, glutamine, histidine, isoleucine, apolipoprotein A1 and A2 in HDL, cholesterol in HDL, High kynurenic acid, a-1-acid glycoprotein, glutamic acid, aspartic acid, glucose, taurine, cystathionine, phenylalanine, triglycerides in HDL, LDL and VLDL, cholesterol in VLDL, phospholipids, apolipoprotein A1 and B in VLDL and IDL,</td>
<td>Amino acid metabolism, gluconeogenesis, lipid metabolism</td>
<td>The metabolic imbalances indicate multi-organ associations, independently of the respiratory symptoms.</td>
</tr>
<tr>
<td>Blasco et al. (2020)</td>
<td>N = 100 45 H, 55 CP</td>
<td>plasma</td>
<td>Targeted LC-HRMS</td>
<td>Major discriminators: Cytosine, indole-3-acetic acid, 2-aminophenol, isoasparagine, 1-NH2-cyclopentan-1-carboxylate, leucine, urate, xanthine</td>
<td>BCAAs metabolism, biotin metabolism, purine metabolism, nicotinate nicotinamide metabolism</td>
<td>Involvement of cytosine metabolism and tryptophan-nicotinamide pathway in COVID-19 infection.</td>
</tr>
<tr>
<td>Zhao et al. (2020)</td>
<td>N = 6 2H, 4CP</td>
<td>Colostrum (breastmilk)</td>
<td>Untargeted LC-MS/MS, MS,</td>
<td>Low indole, indoleacetaldehyde, indole-3-acetic acid, tryptamine, tyrosine, phenylalanine, High Butyryl-carnitine, isobutyryl-carnitine</td>
<td>Aminoacyl-tRNA biosynthesis, aromatic amino acid metabolism, tryptophan metabolism</td>
<td>Breastfeeding with deficiencies in immune-related compounds may not provide adequate defenses to infants.</td>
</tr>
<tr>
<td>Thomas et al. (2020)</td>
<td>N = 52 23 H, 29 CP</td>
<td>serum</td>
<td>Targeted UHPLC-MS</td>
<td>Low palmitate, stearate, resolvins, glucose-6-phosphate, fructose bisphosphate, glyceroldehyde-3-phosphate, DPC, phosphohylcoglycerate, phosphoenolpyruvate, pyruvate, lactate, NADH, GSSG, KEToglutarate, fumarate, kynurenine</td>
<td>Glycolysis, Lipid metabolism, protein degradation, ferroptosis, cyclic AMP-AMPK, energy metabolism</td>
<td>Altered BBC's membrane homeostasis suggests that their respond to oxidative stress is compromised.</td>
</tr>
<tr>
<td>Su et al. (2020)</td>
<td>N = 266 133 H, 133 CP</td>
<td>plasma</td>
<td>Untargeted UHPLC-MS/MS, MS</td>
<td>High N1-methyladenosine, mannosyl, kynurenine, N-palmitoyl-sphingosine</td>
<td>Nucleotide, Amino acid, Carbohydrate, lipid metabolism</td>
<td>Mild to severe: Overactivation of pro-inflammatory mechanisms is accompanied by downregulation of key metabolic pathways and possible hepatic failure.</td>
</tr>
<tr>
<td>Barberis et al. (2020)</td>
<td>N = 161 26 H, 32 CN with symptoms, 103 CP</td>
<td>plasma</td>
<td>Untargeted UPLC-MS/MS, GCxGC-MS</td>
<td>Low glycerol-phosphocholines, sphingomyelins, glycerol-1-phosphothanolamines, High lyso-phosphatidylcholine, acylcarnitines, 2-hydroxybutyrate,</td>
<td>Amino acid metabolism, TCA cycle, aminoacyl tRNA degradation, acachidonic acid metabolism</td>
<td>Host's response to the virus involves lipid deregulation and metabolic dysfunction.</td>
</tr>
</tbody>
</table>

(continued on next page)
<table>
<thead>
<tr>
<th>Author(s), Year</th>
<th>Population Group allocation</th>
<th>Specimen</th>
<th>Method</th>
<th>Metabolic profile in CP</th>
<th>Pathways</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smet et al. (2020)</td>
<td>N = 186 severe CP 165 CP 186 CP</td>
<td>serum</td>
<td>LC-MS</td>
<td>arachidonic, oleic, palmitic, stearic acids, triglycerides</td>
<td>25-OH-Vitamin D</td>
<td>Vitamin D levels are associated with disease stage.</td>
</tr>
<tr>
<td>Grassin-Delyle et al. (2020)</td>
<td>N = 40 12 ARDS CN, 28CP</td>
<td>EBC</td>
<td>PTR-MS</td>
<td>High Methlypent-2-enal, 2,4-octadione, 1-chloroheptane, nonanal</td>
<td></td>
<td>COVID-19 entails a metabolic breathprint.</td>
</tr>
<tr>
<td>Dogan et al. (2020)</td>
<td>N = 85 41 H, 44 CP</td>
<td>serum</td>
<td>Untargeted LC/Q-TOF/MS</td>
<td>Low 1-methyhistidine, LDL 1-LDL, glucose, a 1-acid glycoprotein, triglycerides, alanine, lactate, pyruvate, phenylalanine, VLDL</td>
<td></td>
<td>Lipoprotein metabolism, amino acid metabolism</td>
</tr>
<tr>
<td>Lodge et al. (2021)</td>
<td>N = 84 34 H, 15 CP, 35 CN with symptoms</td>
<td>plasma</td>
<td>Untargeted NMR</td>
<td>Low lipophilic chlorins, siphingolipids</td>
<td></td>
<td>Lipid metabolism</td>
</tr>
<tr>
<td>Wu et al. (2021)</td>
<td>N = 97 48 H, 28 CP, 21 CN</td>
<td>plasma</td>
<td>Targeted LC-MS/MS</td>
<td>High BCAAs and catabolic products, aromatic AAs, acylcarnitines</td>
<td></td>
<td>Lipid metabolism</td>
</tr>
<tr>
<td>Lv et al. (2021)</td>
<td>N = 103 47 H, 56 CP</td>
<td>serum, stool</td>
<td>Untargeted GC–MS</td>
<td>Low 2,4-di-tert-butylphenol, deoxyinosine, 7H-purine, behenic acid, acetic acid, arachidonic acid</td>
<td></td>
<td>Lipid metabolism</td>
</tr>
<tr>
<td>Paez-Franco et al. (2021)</td>
<td>N = 92 27 H, 65 CP (19 mild CP, 46 severe CP)</td>
<td>serum</td>
<td>Untargeted GC–MS</td>
<td>Low cysteine, isoleucine, glutamine, and threonine, glyceric and citric acid</td>
<td></td>
<td>BCAA, glutamate and phenylalanine metabolism, Warburg effect</td>
</tr>
<tr>
<td>Xu et al. (2021)</td>
<td>N = 130 27 H, 103 CP recovered</td>
<td>plasma</td>
<td>Untargeted LC-MS</td>
<td>Low betain, adenosine</td>
<td></td>
<td>Amino acid metabolism</td>
</tr>
<tr>
<td>Danlos et al. (2021)</td>
<td>N = 99 27 CN, 72 CP</td>
<td>Serum/ plasma</td>
<td>Untargeted GC–MS, Targeted UHPLC-MS</td>
<td>Low desaminothreonine, arginine, tryptophan, indole, indole-acetamide, indole-3-acrylic acid, methyl-3-indole-acetate, arachidonic, carnitine esters, phospholipids, sphingosine-1-phosphate, deoxycholic acid</td>
<td></td>
<td>Glycolysis, sugars metabolism, amino acid metabolism</td>
</tr>
</tbody>
</table>
WHO has reasonably established that individuals with underlying health complications, especially non-communicable diseases (NCDs), share elevated risks of developing a more severe infection and, for that reason, guidelines targeting high-risk populations were published a year ago [170]. Systemic and unresolved inflammation during the onset of the disease has emerged as the central factor, tying NCDs with COVID-19 severity. Intervventional strategies targeting modifiable risk factors, that are mainly responsible for the development of NCDs [81], include dietary modifications, micronutrient replenishment, exercise and the adoption of a healthy lifestyle [171–173]. However, consistently to other critically ill recovering patients, convalescent COVID-19 patients may exhibit metabolic abnormalities such as dyslipidemia, cardiovascular complications, lung and kidney injuries, hyperinsulinemia and aberrant glucose uptake [174–176]. These long-term metabolic perturbations drive the development of chronic conditions, such as T2D, even years after recovery [177,178]. The pathophysiology of these issues seems to implicate a combination of psychological, physiological and medical factors, that compose the “metabolic unhealthy” phenotype of post-COVID patients. For instance, impaired metabolic health during the acute ARDS rehabilitation process may result in post-traumatic stress disorders and memory loss, which involve excessive eating habits, reduced motivation for exercise and outdoor activities, thus unfavorable metabolic outcomes. The underlying mechanism suggests that the prevalence of hypoxia and systemic inflammation, treated with ventilatory assistance and brain sedation during the ARDS rehabilitation, leads to post-traumatic stress syndrome and its associated complications [179]. Another potential metabolic burden in the recovery process concerns malnutrition and weight loss in patients exhibiting post-COVID stroke [180]. According to the literature, adipose tissue mass wasting, in an experimentally-induced stroke model, was directly correlated to alterations in lipid metabolism. Specifically, these changes included elevations of free fatty acids and triglycerides, which aggravate cardiovascular manifestations, such as atherosclerosis [181].

Emerging strategies to alleviate ARDS symptomatology have focused on key metabolic pathways. The reported depletions in glucose and folate levels after viral infection have guided the introduction of methotrexate as a recommended rationale for the suppression of the cytokine storm, that mediates systemic inflammation in COVID-19 onset. The drug acts as a folate analog to block viral DNA synthesis and replication [182,183]. Such an approach would be useful both as an anti-viral and as an anti-inflammatory treatment of COVID-19 patients. Merging Metabolomics with Pharmacology, also known as Pharmacometabolomics, is an exciting novel field that offers the ability to address the metabolic impact of a drug, in order to assess its therapeutic efficacy and dosing through pharmacokinetics and pharmacodynamics interactions. The concept of Pharmacometabolomics approaches lies in the extraction of baseline metabolic phenotypes prior to intervention, which will be matched with specific treatment phenotypes. The resulting patterns combined offer information on drug-related individual variations. In this context, patients can be categorized as poor or good responders, according to their metabolic profile before and after drug dosing [184]. Overall, monitoring the levels of the above-mentioned metabolites, as well as integrating the assessment of metabolic health biomarkers in the preventive strategies against post-COVID syndrome, might be of the essence for restoring the metabolic characteristics of the pre-infection state.

7. Expected outcomes

The utmost goal is to employ metabolomics in central healthcare stages to be implemented with current strategies.

A. Metabolomics as a preventive measure for self-protection against infections. In most cases, clinical interventions in critical diseases evade curative effects, as symptoms occur upon advanced stages. In addition, in line with the above, healthcare systems are prompted to manage the symptomatology rather than the origin of infections. The reported depletions in glucose and folate levels after viral infection have guided the introduction of methotrexate as a recommended rationale for the suppression of the cytokine storm, that mediates systemic inflammation in COVID-19 onset. The drug acts as a folate analog to block viral DNA synthesis and replication [182,183]. Such an approach would be useful both as an anti-viral and as an anti-inflammatory treatment of COVID-19 patients. Merging Metabolomics with Pharmacology, also known as Pharmacometabolomics, is an exciting novel field that offers the ability to address the metabolic impact of a drug, in order to assess its therapeutic efficacy and dosing through pharmacokinetics and pharmacodynamics interactions. The concept of Pharmacometabolomics approaches lies in the extraction of baseline metabolic phenotypes prior to intervention, which will be matched with specific treatment phenotypes. The resulting patterns combined offer information on drug-related individual variations. In this context, patients can be categorized as poor or good responders, according to their metabolic profile before and after drug dosing [184]. Overall, monitoring the levels of the above-mentioned metabolites, as well as integrating the assessment of metabolic health biomarkers in the preventive strategies against post-COVID syndrome, might be of the essence for restoring the metabolic characteristics of the pre-infection state.

7. Expected outcomes

The utmost goal is to employ metabolomics in central healthcare stages to be implemented with current strategies.

A. Metabolomics as a preventive measure for self-protection against infections. In most cases, clinical interventions in critical diseases evade curative effects, as symptoms occur upon advanced stages. In addition, in line with the above, healthcare systems are prompted to manage the symptomatology rather than the origin of infections.
of disease, which is viruses in this setting. However, the reported inter-individuality in clinical manifestations arises from the diverse deregulations in the immune system function. The combination of metabolomics methodologies with wearable technologies, such as smartphones or smartwatches, could introduce self-testing and obtain real-time health results [185]. Biomarkers of minimal invasiveness, such as blood spots, saliva, urine and exhaled breath condensates, can be obtained with instructive test kits and collected at home or at the workplace to provide mechanistic information on metabolic health, micronutrient status and environmental cues (e.g., viruses). Particularly, breathomics emerges as a convenient and sensitive strategy in the COVID-19-associated diagnostic biomarkers discovery. The method is based on the identification of volatile organic compounds (VOCs) (e.g., acetone, acetic acid, alcohols, methylene chloride, ethylene glycol, carbon disulfides, formaldehyde) or non-volatiles (nucleic acid, DNA, eicosanoids, microbiota metabolites), as well as inorganic compounds (such as nitric oxide) in exhaled breath [186]. Thus, subjects with hidden metabolic disease and at high risk of developing serious illness upon infection will be identified [131]. These people will be instructed to change their lifestyle and diet to reduce the risk, ensure distancing and follow hygiene guidelines.

B. Metabolomics as a tool to identify high-risk groups among infected individuals during hospital admission. In line with the above, metabolic biomarkers extracted from blood, urine or breath, along with predictive tools, such as machine learning technologies, will serve as a stratification method to discriminate high-risk patients to develop serious COVID-19 disease, even in the absence of comorbidities or old age [138]. The metabolic phenotypes will provide the benefit of a diagnostic window before disease progression, will be informative towards patients’ allocation, as well as quantitative and representative of each patient’s physiological state.

C. Metabolomics in first-line treatment. Early detection of nutritional deficiencies through imbalances in metabolic networks will allow healthcare professionals to provide nutrient-specific guidelines on diet and supplements for low-risk and high-risk individuals. Each category, as well as each patient, will receive a personalized medical nutrition treatment targeting the enforcement of their immune system. Of note, it is essential to establish therapeutic supplement dosages, as special populations, like the elderly, pregnant women, and critically ill patients, usually present with larger-scale deficits, requiring to exceed the recommended dietary allowance in meeting nutritional ends [26,187,188]. In the same context, in the scientific report published by Dietary Guidelines Advisory Committee, it is recommended to increase the intake of certain nutrients whose deficiencies are associated with adverse health conditions [189]. The application of these strategies not only will deal with the acute health consequences from COVID-19 and improve patients’ quality of life, but it will reduce hospital admissions in the overwhelmed healthcare systems.

D. Metabolomics in severe COVID-19 cases. Healthcare professionals will be able to shape their medical nutrition treatment, according to the patient’s metabolic health and nutritional deficiencies, in parallel with standard anti-viral treatment. The implementation of a combinatorial approach will expedite patients’ recovery time, minimizing the risk of irreversible tissue damage and the length of hospital stay. Another aspect of this approach is the effective prevention of post-COVID complications by maintaining a mild and coordinated immune response level and fine-tuning the metabolic imbalances.
E. Metabolomics in post-COVID syndrome. Individuals recovered from the infection may take at-home self-tests, which will be remotely assessed by their physicians, in order to take actionable measures. Thus, optimization of the medical nutrition plan during follow-up will prevent the onset or alleviate the severity of COVID-19-related long-term health complications. Overall, metabolic health assessment will serve as a supportive tool for individuals that have recovered from COVID-19 to target post-COVID complications, either metabolic or quality-of-life related.

8. Future steps

Rapid technological advancements have put metabolomics at the center of biomarker discovery of NCDS with proven utility in disorders with known metabolic hallmarks (e.g., cardiovascular disease, cancer, autoimmune diseases). There is strong evidence that COVID-19 should be handled as a disease with metabolic features, and metabolomics is the only tool that can comprehensively study metabolic networks [190]. Now, we are called to combine tools and knowledge from relatively unrelated fields, i.e., virology and biochemistry, to address the COVID-19 pandemic and be prepared for future outbreaks. Despite that the assessment of metabolic health and micronutrient status is a widely studied field. COVID-19 is an evolving field that requires additional research. We need to set up a strategy in order to define those biomarkers that will provide the diagnostic advantage over disease progression and serve as therapeutic targets. In this article, we propose a panel of biomarkers (Table 2) that are involved in central metabolic pathways, are related to early metabolic derangements, and some of them have been associated with the presence of COVID-19, which could be used as a starting point and be validated in clinical trials (Table 1). However, there needs to be caution as the design of clinical trials is of the highest importance for the generation of conclusive results and the accurate comparability between trials. The ongoing ventures, evaluating nutritional deficits and COVID-19 risk, report considerable discrepancies due to poor study designs, lack of established methodologies and self-reported data [191]. Metabolomic profiling of selected biomarkers needs to be tested in a large number of COVID-19 patients and from different geographical regions, in addition to the medical and nutritional history and clinical laboratory parameters. Special attention should also be given to the methodological details given the sensitivity of metabolite concentrations on handling, storage and method. In addition, we need to establish how this metabolic profile is affected by the metabolic rewiring through medical nutrition treatment and relate it to the clinical phenotype. Thus, metabolite-based, artificial intelligence predictive models will be developed as decision-making tools that will match the metabolic fingerprint to a specific treatment. As described elsewhere, large-scale interventional metabolomic studies harnessing the information on nutritional habits, the optimal dosing of nutritional supplements, as well as the assessment of the synergistic effect of selected nutrients are crucial [71]. Overall, it is becoming apparent that we already have deciphered the scientific and technological background to target the host’s metabolism and improve the immune system response; thus, we need to support their implementation in clinical practice.

9. Conclusions

At the present time, COVID-19 is in the primal focus, as the need for a successful treatment escalates. The postgenomic era focuses on the emerging field of Metabolomics, the most downstream stage of omics strategies, and the molecular reflection of phenotype. The metabolome is inherently dynamic, as metabolic reactions occur incessantly and engage intracellular, extracellular as well as environmental interactions. COVID-19, although a new infectious disease, shares common pathological mechanisms with other infections, revealing its metabolic perplexity in infection susceptibility, treatment and recovery [190]. Thus, with this article, we propose that metabolic profiling can have multiple applications, including a. At-home risk for infection calculator and nutrition guide, b. A screening tool of high-risk COVID-19 admitted patients, c. First-line treatment guide for mildly ill patients to reduce the risk for hospitalization d. Supportive treatment for critically ill patients to reduce recovery time and risk of post-COVID complications, e. Follow-up metabolic status assessment tool and nutrition guide. As more clinical trials report their findings, the complex interplay between the host’s metabolism and COVID-19 progression will be unwound. From a clinical perspective, though, insulin resistance and micronutrient deficiencies are viable targets as they represent early signs of metabolic deregulation and can be easily modulated through medical nutrition treatment. Tuned actions to establish a unified strategy will facilitate the realization of these goals and equip the healthcare system against the current and future pandemics.

Author contributions

All authors contributed to the conception, literature search, figure design and writing of the manuscript.

Sources of funding

No external funding was received. Declaration of competing interest

The authors have a conflict of interest to declare.

References

D. Tsoukalas, E. Sarandi and S. Georgaki


